MedTrace Logo

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

NCT01307267 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2020-03-17

Study results available
· View outcomes & findings →

Summary

A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).

Conditions

  • Lymphoma, Non-Hodgkin
  • Lymphoma, Follicular
  • Lymphoma, Large B-Cell, Diffuse
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Renal Cell
  • Carcinoma, Squamous Cell of Head and Neck
  • Malignant Melanoma

Interventions

DRUG

PF-05082566

Intravenous, Dose escalation, once per month

DRUG

rituximab

Intravenous, 375 mg/m2, once per week for 4 weeks

DRUG

PF-05082566

IV, Dose escalation, once per month

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-21
Primary Completion
2019-02-20
Completion
2019-02-20

Countries

  • United States
  • Australia
  • France
  • Italy
  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01307267 on ClinicalTrials.gov